Mandate

Vinge assists Nuevolution in connection with Amgen’s cash offer

Vinge has assisted Nuevolution AB (publ) (“Nuevolution”) in connection with the cash offer to the shareholders in Nuevolution by Amgen Inc. (“Amgen”).

Nuevolution is a molecule drug discovery biotech company, listed on Nasdaq Stockholm. 

Amgen is one of the world’s leading biotechnology companies, with a vision deeply rooted in innovative science. Amgen’s shares are listed on Nasdaq in the United States.

Amgen offers SEK 32.50 in cash for every share in Nuevolution. The offer value amounts to approximately SEK 1,610 million.
 
Vinge’s team has primarily consisted of David Andersson, Dain Hård Nevonen, Ludvig Frithiof and William Kåge.

Related

Vinge has advised Fortinova Fastigheter in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Fortinova Fastigheter AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm. The prospectus was published on 12 November 2025 and the trading on Nasdaq Stockholm commenced on 19 November 2025, five years to the day since the first listing.
November 19, 2025

Vinge has advised Lagercrantz Group on the acquisition of Sit Right and Enskede Hydraul

Lagercrantz Group AB (publ) has acquired 70 percent of the shares in the two Swedish companies Sit Right AB and Enskede Hydraul AB, which are leading operators in products and aftermarket parts for forestry and construction machinery in Europe.
November 07, 2025

Vinge advises the founders of NOOS Digital in connection with the merger with Rocket Revenue and 56K Digital

Following the recent merger between Rocket Revenue and 56K Digital, the group now takes its next step by joining forces with NOOS Digital. The three companies will integrate into one of the Nordic region’s most comprehensive partners for digital transformation and business acceleration.
November 04, 2025